ARTICLE | Product Development
Milestone says trial design trips up etripamil in tachycardia Phase III
March 24, 2020 1:03 AM UTC
Milestone’s at-home paroxysmal supraventricular tachycardia candidate did not meet its primary endpoint in the Phase III NODE-301 study, but the company believes the miss was due to trial design and that the data support efficacy.
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is continuing to evaluate etripamil nasal spray in the second part of the trial, NODE-301B, in randomized patients who hadn’t experienced a cardiac event by the time NODE-301 had reached its targeted number of adjudicated supraventricular tachycardia (SVT) events. NODE-301B results will be analyzed as a separate data set...
BCIQ Company Profiles